Strategy & Milestones

Our clinical strategy harnesses the unique capabilities of
oncolytic viruses for effective cancer treatment

Our goal is to deliver clinical benefits to patients, such as halting the progression of cancer and enhancing survival rates. In addition to continuous innovation of our OV backbone, Virogin is reimagining and redesigning clinical trial strategies, pushing the envelope to fully unleash the potential of oncolytic virotherapy. 

• Targeting the highest unmet medical needs
• Enrichment of potential responders based on biomarkers to achieve significantly prolonged OS (overall survival) of late-stage cancer patients
• Expertise in navigating the regulatory pathway for accelerated approvals
• Global clinical data sharing for approvals of multiple regions
• Systemic and local treatment: intravenous and intra-tumoral

Our Regulatory Milestones